Closely-held Interface Biologics (IBI) has appointed Wendy Naimark as VP of research & development.
Wendy joins IBI after five years as senior director, clinical and preclinical sciences at 480 Medical, an early-stage drug delivery device company in the cardiovascular space. Previously, she spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of interventional cardiology, peripheral interventions, imaging, endosurgery, urology/women’s health and neurovascular.
“It’s rare that you find such a capable scientist with experience in both large medical device companies and early-stage startups,” Tom Reeves, president and CEO of Interface, said in a statement.
Ms. Naimark added that “having the opportunity to join Tom and the IBI team at this point in the company’s trajectory, is an exciting opportunity and one I fully embrace.”
